Tag: prognostic value

Negotiations of Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD

Body weightThe present study confirms previous data on the effect of muscle mass on mortality in patients with COPD. In stable patients, MD is associated to an increased risk of death. In addition, as a remarkable finding, we show that the prognostic influence of muscle mass can be assessed by determining the MAMA, an inexpensive, simple, and rapidly obtained anthropometric measure. MAMA < p25 was found to be a poor prognosis marker, exerting an influence in our series superior to that of other anthropometric parameters such as BMI or FFMi. In underweight patients, the presence of muscle depletion did not contribute significant prognostic information. However, those subjects with normal body weight or overweight status who presented MAMA < p25 had a poorer prognosis.

Outcomes of Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD

Normal-Weight

Subject Characteristics

A total of 114 patients with a diagnosis of COPD were studied. Of these, 18 patients (15.8%) were excluded for different reasons: 7 patients (6.1%) with decompensated cor pulmonale, 3 patients (2.6%) with liver cirrhosis, 2 patients (1.7%) with neoplasms, 2 patients (1.7%) due to sustained oral corticosteroid use, 2 patients (1.7%) because of heart failure, 1 patient (0.9%) with chronic renal failure, and another patient (0.9%) due to malabsorption syndrome. A total of 96 patients were therefore finally included (all male; mean age, 69 ± 9 years [± SD]). Table 1 shows the baseline characteristics of these patients.

Investigation about Mid-Arm Muscle Area Is a Better Predictor of Mortality Than Body Mass Index in COPD

COPD

Subjects

A prospective study was made of a cohort of 114 patients with stable COPD. The patients were recruited in the last trimester of the year 2000, with a subsequent follow-up period of 3 years. The diagnosis of COPD was based on a current or previous smoking history (> 20 packs-year), clinical assessment, and pulmonary function testing. The postbronchodilator FEV1, expressed as a percentage of the theoretical value, was used to classify the patients according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) committee criteria. Patients exhibiting > 15% reversibility in the bronchodilator test were according to the latest excluded from the study, as were those subjects with a previous diagnosis of bronchial asthma, bronchiectasis, cystic fibrosis, upper airways obstruction, or bronchiolitis related to systemic disorders. Patients with concomitant diseases capable of altering nutritional status (heart failure, liver cirrhosis, decompensated diabetes, chronic renal failure, uncontrolled thyroid pathology, neoplasms, decompensated chronic cor pulmonale, sustained systemic steroid use) were also excluded. The patients were required to be in a stable phase of COPD, defined as the absence of disease exacerbations in the 2 months preceding the study held due to My Canadian Pharmacy.